Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNatwest Regulatory News (NWG)

Share Price Information for Natwest (NWG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 305.00
Bid: 304.30
Ask: 304.50
Change: 1.80 (0.59%)
Spread: 0.20 (0.066%)
Open: 304.90
High: 307.20
Low: 304.00
Prev. Close: 303.20
NWG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Tender Offer

22 Sep 2020 13:21

RNS Number : 7532Z
NatWest Group plc
22 September 2020
 

 

 

September 22, 2020

NATWEST GROUP plc - RESULTS OF TENDER OFFERS FOR CERTAIN OF ITS OUTSTANDING NOTES

 

NatWest Group plc (the "Offeror") is today announcing the final results of its previously announced cash tender offers (each, an "Offer" and, together, the "Offers") for any and all of certain series of its U.S. dollar denominated notes set out in the table below (the "Notes").

The Offers were made on the terms and subject to the conditions set out in the offer to purchase dated September 14, 2020 (the "Offer to Purchase") and the related Notice of Guaranteed Delivery (together, the "Offer Documents"). Capitalized terms not otherwise defined in this announcement have the same meaning as in the Offer to Purchase.

Based on information provided by the Tender Agent, $1,967,908,000 in aggregate principal amount of the Notes were validly tendered and not validly withdrawn by 5:00 p.m., New York City time, on September 21, 2020 (the "Expiration Deadline"), as more fully set forth below. The Offeror has accepted all Notes that were validly tendered and not validly withdrawn prior to the Expiration Deadline. In addition, $9,418,000 in aggregate principal amount of the Notes were tendered using the guaranteed delivery procedures. The Settlement Date is expected to be September 24, 2020.

 

The table below sets forth, among other things, the principal amount of each series of Notes validly tendered and not validly withdrawn at or prior to the Expiration Deadline:

Title of Security

Issuer

ISIN/CUSIP

Principal Amount Outstanding(1)

Aggregate Principal Amount Tendered Excluding Notes Tendered Using Guaranteed Delivery Procedures

 

Aggregate Principal Amount Tendered Using Guaranteed Delivery Procedures

Purchase Price(2)

6.425% Non-Cumulative Trust Preferred Securities ("Trust Securities")

RBS Capital Trust II

US74927PAA75

74927PAA7

$393,573,000(4)

$251,681,000

$4,207,000

$1,556.87

7.648% Dollar Perpetual Regulatory tier One Securities, Series 1 ("PROs")

The Royal Bank of Scotland Group plc(3)

US780097AH44

780097AH4

$761,746,000

$631,491,000

$793,000

$1,547.47

6.125% Subordinated Tier 2 Notes due 2022 ("2022 Notes")

The Royal Bank of Scotland Group plc (3)

US780099CE50

780099CE5

$2,250,000,000

$630,064,000

$2,691,000

$1,098.79

6.100% Subordinated Tier 2 Notes due 2023 ("2023 Notes")

The Royal Bank of Scotland Group plc(3)

US780097AY76

780097AY7

$1,000,000,000

$454,672,000

$1,727,000

$1,116.01

(1) As of the commencement date of the Offers.

(2) Per $1,000 principal amount of the Notes (as defined herein) validly tendered and accepted for purchase.

(3) Currently NatWest Group plc.

(4) Excluding $256,427,000 principal amount of 6.425% Non-Cumulative Trust Preferred Securities, which are held by the Offeror as of the date hereof and are deemed not to be outstanding.

 

 

 

 

FURTHER INFORMATION

 

Lucid Issuer Services Limited acted as tender agent for the Offers. NatWest Markets Securities Inc., an affiliate of the Offeror, acted as Global Arranger and Lead Dealer Manager and Goldman Sachs & Co. LLC and UBS Securities LLC (together with NatWest Markets Securities Inc.) acted as Dealer Managers. Questions regarding the Offers should be directed to NatWest Markets Securities Inc. at +44 20 7678 522, Goldman Sachs & Co. LLC at +1 800 828 3182, +1 212 357-0215 (Collect) or +44 20 7552 6157 (U.K.) and UBS Securities LLC at +1 888 719-4210, + 1 203 719 4210 (Collect) or +44 20 7568 1121 (U.K.).

 

FORWARD-LOOKING STATEMENTS

 

From time to time, we may make statements, both written and oral, regarding our assumptions, projections, expectations, intentions or beliefs about future events. These statements constitute "forward-looking statements". We caution that these statements may and often do vary materially from actual results. Accordingly, we cannot assure you that actual results will not differ materially from those expressed or implied by the forward-looking statements. You should read the sections entitled "Risk Factors" in the Offer to Purchase, in our Annual Report, Q1 2020 Interim Report and H1 2020 Interim Report and "Forward-Looking Statements" in our Annual Report, Q1 2020 Interim Report and H1 2020 Interim Report.

 

Any forward-looking statements made herein or in the documents incorporated by reference herein speak only as of the date they are made. Except as required by the U.K. Financial Conduct Authority (the "FCA"), any applicable stock exchange or any applicable law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in the Offer to Purchase or the documents incorporated by reference herein to reflect any changes in expectations with regard thereto or any new information or any changes in events, conditions or circumstances on which any such statement is based. The reader should, however, consult any additional disclosures that we have made or may make in documents we have filed or may file with the SEC.

 

Legal Entity Identifiers

 

NatWest Group plc

2138005O9XJIJN4JPN90

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTEEAANAAFLEEFA
Date   Source Headline
19th Jan 20245:08 pmRNSTransaction in Own Shares
18th Jan 20245:39 pmRNSTransaction in Own Shares
17th Jan 20245:42 pmRNSTransaction in Own Shares
16th Jan 20245:30 pmRNSTransaction in Own Shares
15th Jan 20245:58 pmRNSTransaction in Own Shares
12th Jan 20245:02 pmRNSTransaction in Own Shares
11th Jan 20245:13 pmRNSTransaction in Own Shares
10th Jan 20245:28 pmRNSTransaction in Own Shares
9th Jan 20245:04 pmRNSTransaction in Own Shares
8th Jan 20245:18 pmRNSTransaction in Own Shares
5th Jan 20245:24 pmRNSTransaction in Own Shares
4th Jan 20245:09 pmRNSTransaction in Own Shares
3rd Jan 20245:39 pmRNSTransaction in Own Shares
3rd Jan 20244:00 pmRNSDirector/PDMR Shareholding
3rd Jan 202410:38 amRNSHolding(s) in Company
2nd Jan 20245:24 pmRNSTransaction in Own Shares
29th Dec 202312:47 pmRNSTotal Voting Rights
29th Dec 202310:30 amRNSDirector/PDMR Shareholding
28th Dec 20235:37 pmRNSTransaction in Own Shares
27th Dec 20235:18 pmRNSTransaction in Own Shares
22nd Dec 20231:27 pmRNSTransaction in Own Shares
21st Dec 20235:23 pmRNSTransaction in Own Shares
20th Dec 20235:35 pmRNSTransaction in Own Shares
19th Dec 20235:33 pmRNSTransaction in Own Shares
19th Dec 20233:00 pmRNSDirector/PDMR Shareholding
18th Dec 20235:31 pmRNSTransaction in Own Shares
15th Dec 20235:25 pmRNSTransaction in Own Shares
15th Dec 20239:00 amRNSKey findings from Phase 2 of Travers Smith review
13th Dec 20235:32 pmRNSTransaction in Own Shares
12th Dec 20235:29 pmRNSTransaction in Own Shares
11th Dec 20239:38 amRNSHolding(s) in Company
8th Dec 20239:46 amRNSPublication of a Prospectus
7th Dec 20235:18 pmRNSTransaction in Own Shares
6th Dec 20235:30 pmRNSTransaction in Own Shares
5th Dec 20235:07 pmRNSTransaction in Own Shares
4th Dec 20235:12 pmRNSTransaction in Own Shares
1st Dec 20235:41 pmRNSTransaction in Own Shares
1st Dec 20239:52 amRNSTotal Voting Rights
29th Nov 20235:57 pmRNSTransaction in Own Shares
28th Nov 20235:31 pmRNSTransaction in Own Shares
27th Nov 20235:35 pmRNSTransaction in Own Shares
24th Nov 20235:34 pmRNSTransaction in Own Shares
23rd Nov 20235:27 pmRNSTransaction in Own Shares
23rd Nov 20233:39 pmRNSDividend Declaration
22nd Nov 20235:39 pmRNSTransaction in Own Shares
22nd Nov 20238:30 amRNSJPMorgan UK Leaders Conference
21st Nov 20235:54 pmRNSTransaction in Own Shares
21st Nov 20232:00 pmRNSDirector/PDMR Shareholding
20th Nov 20235:09 pmRNSTransaction in Own Shares
16th Nov 20235:33 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.